Forte Biosciences (FBRX) Projected to Post Earnings on Thursday

by · The Cerbat Gem

Forte Biosciences (NASDAQ:FBRX – Get Free Report) is expected to release its Q3 2025 results before the market opens on Thursday, November 13th. Analysts expect Forte Biosciences to post earnings of ($1.04) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Tuesday, November 18, 2025 at 4:00 PM ET.

Forte Biosciences (NASDAQ:FBRX – Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported ($0.96) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.21) by $0.25. On average, analysts expect Forte Biosciences to post $-12 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Forte Biosciences Price Performance

Shares of NASDAQ:FBRX opened at $13.67 on Tuesday. The firm has a market capitalization of $169.92 million, a PE ratio of -1.99 and a beta of 2.98. The business has a 50-day moving average of $12.87 and a two-hundred day moving average of $11.18. Forte Biosciences has a 12 month low of $4.81 and a 12 month high of $28.68.

Institutional Investors Weigh In On Forte Biosciences

Large investors have recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. increased its stake in Forte Biosciences by 23.8% during the 3rd quarter. Envestnet Asset Management Inc. now owns 23,347 shares of the company’s stock worth $350,000 after buying an additional 4,491 shares during the period. Mink Brook Asset Management LLC purchased a new stake in shares of Forte Biosciences during the second quarter worth about $503,000. Geode Capital Management LLC lifted its stake in shares of Forte Biosciences by 6.7% in the second quarter. Geode Capital Management LLC now owns 64,110 shares of the company’s stock worth $829,000 after acquiring an additional 4,028 shares in the last quarter. Perceptive Advisors LLC purchased a new position in Forte Biosciences in the second quarter valued at about $882,000. Finally, Adage Capital Partners GP L.L.C. purchased a new position in Forte Biosciences in the second quarter valued at about $4,310,000. 77.63% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on FBRX. Chardan Capital reiterated a “buy” rating and set a $61.00 target price on shares of Forte Biosciences in a report on Friday, August 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Forte Biosciences in a research report on Friday, October 31st. Guggenheim initiated coverage on shares of Forte Biosciences in a research report on Monday, August 18th. They issued a “buy” rating and a $75.00 price objective for the company. Finally, Wall Street Zen raised shares of Forte Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, November 1st. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $68.00.

Get Our Latest Stock Report on FBRX

Forte Biosciences Company Profile

(Get Free Report)

Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.

Further Reading